| abstract |
The present disclosure is primarily a novel Formula I: CGRP receptor antagonist. (Including pharmaceutically acceptable salts). The disclosure also includes pharmaceutical compositions and CGRP-related diseases [migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, burns, circulatory shock, menopause flushing, airway inflammatory diseases (eg, asthma) , And chronic obstructive pulmonary disease (COPD)]. |